

Letter to the Editor

Racial comparison of filaggrin null mutations in asthmatic patients with atopic dermatitis in a US population

To the Editor:

Filaggrin (filament-aggregating protein) is encoded by the filaggrin (*FLG*) gene located within the epidermal differentiation complex along with 30 other genes on chromosome 1q21. Filaggrin is synthesized as a large precursor, profilaggrin, and is expressed in the upper layers of the epidermis. The discovery of loss-of-function mutations in the gene *FLG* has improved our understanding of the pathophysiology of atopic dermatitis (AD) and associated atopic diseases.^{1,2} The presence of a filaggrin loss-of-function (*FLG* null) mutation has been estimated to increase the odds of having AD by more than 3-fold.³ Furthermore, the presence of *FLG* null mutations and AD confers an increased risk for the development of asthma.⁴ In a Scottish population, the R501X mutation of *FLG* was associated with asthma disease severity even in the absence of a history of eczema.⁵ Prevalent *FLG* null mutations vary by the race/ethnicity of the population and by the country studied.^{1,2,6} There are no studies comparing the association of *FLG* null mutations and the diagnosis of asthma or symptoms of asthma among those with AD between racial groups within the United States.

In a cross-sectional evaluation of children with AD and asthma, we evaluated the most common European *FLG* null mutations: R501X, 2282del4, R2447X, and S3247X. We studied the association of these mutations and the diagnosis of asthma or the frequency of wheezing in white and African American children with AD. All the children enrolled in our study were participants in the Pediatric Eczema Elective Registry (PEER; www.thepeerprogram.com).⁷ PEER is an ongoing, prospective, 10-year observational registry that is part of a long-term postmarketing safety commitment by Valeant Pharmaceuticals International (formally the responsibility of Novartis) to the US Food and Drug Administration and the European Drug Agency. All children enrolled in this nationwide registry have physician-confirmed diagnosis of AD. At 2 points in time, PEER captured information on other atopic diagnoses, including asthma. The survey instruments used in PEER have been reported elsewhere.⁷

The *FLG* null mutations were genotyped by using custom-made TaqMan allelic discrimination assays (Applied Biosystems, Foster City, Calif) according to previously published protocols.⁷ Ancestral race was inferred for all study subjects by using a previously described panel of ancestral informative markers that revealed minimal differences between inferred race and self-reported race.^{8,9}

To investigate the association between *FLG* null mutations and the diagnosis of asthma, we used a logistic regression model. To examine the association between *FLG* null mutations and the frequency of wheezing, we used a proportional odds type of ordered logistic regression model. This is also called a proportional odds model. Wheezing was categorized as no episodes, 1 to 3 episodes, 4 to 12, and more than 12 episodes in the previous year. All effect estimates were presented with 95% CIs. All analyses were conducted with STATA 12.1 (StataCorp, College Station, Tex).

DNA was available from 857 PEER participants. The demographic and descriptive information have been previously

published.⁹ Briefly, 52.1% of the full cohort was female and 43.6% were self-described as African American. The average age of enrollment was 7.2 years, and the average age of disease onset was 2.1 ± 2.7 years (median <1 year). Table I contains a report of demographic information for those diagnosed with asthma. Table II displays the associations between *FLG* null mutations, a diagnosis of asthma, and the frequency of wheezing. Only the R501X mutation was associated with an increased likelihood of asthma as well as an increased likelihood of more frequent wheezing. Few African Americans had prevalent mutations. However, the magnitude of these effect estimates was generally similar to that in whites.

The presence of a R501X *FLG* null mutation was associated with a diagnosis of asthma in our cohort of children with atopic dermatitis (odds ratio, 1.77; 95% CI, 1.09-2.90; $P = .021$). This association has been previously described, but only in European populations. Unlike previous studies, we did not find an association with the combined genotype but we did find an association with increased asthma-related symptoms (ie, wheezing). This has not been previously described in a US population. Like our study, a study by Palmer et al⁵ found a greater association between R501X and increasing severity of asthma. Like previous studies, the mutations were statistically significant only in the white population (see Table II). However, we show that while the R501X mutation is rarely seen in African Americans, those few with this mutation have not a significant but elevated risk of asthma.

Recent academic society meetings including the American Academy of Allergy, Asthma & Immunology have featured presentations discussing the impact of filaggrin on various disease states.¹⁰ Their data suggest that there is opportunity to further study this topic. We do this by focusing on the filaggrin mutations that seem to be associated with asthma in the US population. Our findings validate previous studies that have described associations of R501X null mutations with asthma. They add to the previous literature by demonstrating that all those with the R501X mutations are more likely to frequently wheeze. Lastly, our results expand on the previous literature by comparing mutations interracially, thus allowing for the description of significant mutations in the genetically diverse US population. Prior studies have focused on European populations. We believe that there is a need to study the possible impact of filaggrin mutations in African Americans because the mutations in this group have not been characterized. Our findings provide a starting point for further research on filaggrin mutations in this group.

Jackie P.-D. Garrett, MD^{a,b}

Ole Hoffstad, MA^c

Andrea J. Apter, MD, MSc, MA^d

David J. Margolis, MD, PhD^{c,e}

From ^athe Children's Hospital of Philadelphia and ^cthe Department of Epidemiology and Biostatistics, ^bPerelman School of Medicine at University of Pennsylvania; ^dSection of Allergy and Immunology, Pulmonary, Allergy and Critical Care Division, and ^ethe Department of Dermatology, Hospital of the University of Pennsylvania, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pa. E-mail: jpdorce@yahoo.com.

Disclosure of potential conflict of interest: A. J. Apter has been supported by the National Institutes of Health (NIH) (grant no. R01A056755) and by UpToDate, AstraZeneca, and Bristol Myers Squibb. J. P.-D. Garrett has been supported by

TABLE I. Basic demographic information of the study population

Variable	Full cohort	Any FLG null	R501X	2282del4	R2447X	S3247X
n (%)	447	106 (23.7)	44 (10.2)	30 (7.0)	11 (2.5)	21 (4.7)
Female (%)	225 (50.3)	49 (21.8)	19 (8.4)	14 (6.2)	5 (2.2)	11 (4.9)
Male (%)	217 (48.5)	57 (26.3)	25 (11.5)	16 (7.4)	6 (2.8)	10 (4.6)
White (%)	224 (50.1)	84 (37.5)	38 (17.0)	27 (12.1)	13 (5.8)	6 (2.7)
African American (%)	201 (45.0)	21 (10.4)	8 (4.0)	2 (1.0)	6 (3.0)	5 (2.5)

TABLE II. Odds ratios (ORs) and 95% CI for the association between *FLG* null mutations and the diagnosis of asthma and proportional odds ratios (PORs) and 95% CI for the association between *FLG* null mutations and the frequency of wheezing

Gene name	Unadjusted	Unadjusted white	Unadjusted African Americans	Adjusted for gender for entire population	Adjusted for gender among whites	Adjusted for gender among African Americans
Diagnosis of asthma						
R501X	OR 1.77 (1.09-2.90) <i>*P</i> = .021	OR 1.81 (1.06-3.08) <i>*P</i> = .029	OR 1.25 (0.47-3.37) <i>P</i> = .654	OR 1.76 (1.08-2.88) <i>*P</i> = .024	OR 1.79 (1.05-3.06) <i>*P</i> = .032	OR 1.25 (0.46-3.39) <i>P</i> = .659
2282del4	OR 1.04 (0.64-1.70) <i>P</i> = .882	OR 0.99 (0.59-1.67) <i>P</i> = .971	OR 1.30 (0.22-7.90) <i>P</i> = .772	OR 1.04 (0.63-1.70) <i>P</i> = .878	OR 0.99 (0.59-1.68) <i>P</i> = .980	OR 1.24 (0.20-7.56) <i>P</i> = .816
R2447X	OR 1.67 (0.61-4.57) <i>P</i> = .314	OR 0.91 (0.29-2.87) <i>P</i> = .875	OR 1 (0.81-5.62) <i>P</i> = .124	OR 1.62 (0.59-4.42) <i>P</i> = .351	OR 0.85 (0.27-2.68) <i>P</i> = .776	OR (not estimable)
S3247X	OR 1.12 (0.58-2.15) <i>P</i> = .738	OR 1.23 (0.57-2.66) <i>P</i> = .601	OR 2.14 (0.81-5.62) <i>P</i> = .124	OR 1.13 (0.59-2.18) <i>P</i> = .713	OR 0.125 (0.58-2.70) <i>P</i> = .576	OR 2.13 (0.81-5.61) <i>P</i> = .128
Frequency of wheezing						
R501X (Filaggrin)	POR 1.83 (1.18-2.85) <i>*P</i> = .007	POR 1.92 (1.18-3.13) <i>*P</i> = .009	POR 1.36 (0.54-3.45) <i>P</i> = .513	POR 1.78 (1.15-2.76) <i>*P</i> = .010	POR 1.84 (1.12-3.00) <i>*P</i> = .015	POR 1.36 (0.54-3.43) <i>P</i> = .515
2282del4	POR 1.09 (0.68-1.76) <i>P</i> = .716	POR 1.09 (0.66-1.81) <i>P</i> = .739	POR 0.97 (0.19-4.72) <i>P</i> = .970	POR 1.08 (0.67-1.74) <i>P</i> = .763	POR 1.06 (-0.32 to 0.71) <i>P</i> = .812	POR 0.91 (0.64-1.77) <i>P</i> = .905
R2447X	POR 1.36 (0.57-3.27) <i>P</i> = .485	POR 1.37 (0.66-2.84) <i>P</i> = .393	POR 4.61 (0.85-22.5) <i>P</i> = .059	POR 1.30 (0.54-3.11) <i>P</i> = .563	POR 0.73 (0.25-2.13) <i>P</i> = .566	POR 4.92 (1.00-24.23) <i>P</i> = .050
S3247X	POR 1.36 (0.72-2.55) <i>P</i> = .347	POR 0.79 (0.27-2.30) <i>P</i> = .671	POR 2.17 (0.95-4.96) <i>P</i> = .067	POR 1.34 (0.71-2.52) <i>P</i> = .363	POR 1.35 (0.65-2.80) <i>P</i> = .422	POR 2.12 (0.92-4.84) <i>P</i> = .074

**P* < .05.

one or more grants from the NIH (NIH Research Grant Supplement, grant no. 5R01AR056755-04), the AAAAI (AAAI Fellowship of Excellence training grant), and the ACAAI. D. J. Margolis has been supported by one or more grants from the NIH (grant no. R01AR056755) and from Valeant Pharmaceuticals (grant funding for PEER). O. Hoffstad declares that he has no relevant conflicts of interest.

REFERENCES

- Rodriguez E, Baurecht H, Herberich E, Wagenpfeil S, Brown SJ, Cordell HJ, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. *J Allergy Clin Immunol* 2009;123:1361-70.e7.
- Henderson J, Northstone K, Lee SP, Liao H, Zhao Y, Pembrey M, et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. *J Allergy Clin Immunol* 2008;121:872-7.e9.
- Brown SJ, McLean WH. One remarkable molecule: filaggrin. *J Invest Dermatol* 2012;132:751-62.
- McLean WH, Palmer CN, Henderson J, Kabesch M, Weidinger S, Irvine AD. Filaggrin variants confer susceptibility to asthma. *J Allergy Clin Immunol* 2008; 121:1294-5, author reply 5-6.
- Palmer CN, Ismail T, Lee SP, Terron-Kwiatkowski A, Zhao Y, Liao H, et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. *J Allergy Clin Immunol* 2007;120:64-8.
- van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. *BMJ* 2009;339:b2433.
- Kapoor R, Menon C, Hoffstad O, Bilker W, Leclerc P, Margolis DJ. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. *J Am Acad Dermatol* 2008;58:68-73.
- Stefflova K, Dulik MC, Barnholtz-Sloan JS, Pai AA, Walker AH, Rebbeck TR. Dissecting the within-Africa ancestry of populations of African descent in the Americas. *PLoS One* 2011;6:e14495.
- Margolis DJ, Apter AJ, Gupta J, Hoffstad O, Papadopoulos M, Campbell LE, et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. *J Allergy Clin Immunol* 2012;130:912-7.
- The American Academy of Allergy, Asthma & Immunology 2013 annual conference. Course 1210: Advances and novel approaches in the genetics of allergic diseases: 21st century (Part I); Presidential Plenary Session: Role of filaggrin in human disease and allergic sensitization.

<http://dx.doi.org/10.1016/j.jaci.2013.07.005>